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sion (N = 556) or anxiety (N = 158) in addition to
migraine equated to signiﬁcantly greater outpatient, pre-
scription drug, and total medical costs compared to a
healthy comparator group. The differential in total costs
(medical plus productivity) between migraine sufferers
with comorbid anxiety ($4562, p < 0.0001) or comorbid
depression ($6193, p < 0.0001) and the healthy cohort
was substantially greater than the differential between
migraine sufferers without these comorbidities and their
healthy matches ($3638, p < 0.0001). CONCLUSIONS:
These results demonstrate and quantify the economic
burden in terms of direct and indirect costs to employers
of migraine alone and migraine in conjunction with
depression or anxiety.
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OBJECTIVE: To assess, via Monte Carlo simulation, the
per-attack drug acquisition cost and effectiveness (pro-
portion of patients pain-free two hours post-dose) of ﬁve
oral triptan strategies for treatment of acute migraine
headaches. METHODS: A Monte Carlo simulation
model was used to estimate the average number of
patients needed to treat (NNT), relative to placebo, to
achieve the efﬁcacy endpoint of one pain-free two hours
post-dose (pain-free patient). Efﬁcacy data was obtained
from a published meta-analysis of 53 triptan-speciﬁc 
clinical trials. A normal distribution for the proportion of
pain-free patients was used and was based on the means
and 95% conﬁdence intervals reported in the meta-
analysis. Single-dose acquisition costs, based on average
wholesale prices (2002US$), were applied to the NNT
results, allowing for a per-attack assessment of the cost
per pain-free patient. Oral triptans almotriptan, nara-
triptan, rizatriptan, sumatriptan and zolmitriptan were
assessed in the simulation. RESULTS: After 10,000 
iterations, the mean NNT (95% CI) to achieve one 
pain-free patient was 3.31 (2.97–3.71) for rizatriptan,
4.16 (2.83–6.54) for zolmitriptan, 5.06 (3.32–8.53) for
almotriptan, 5.14 (4.50–5.92) for sumatriptan and 7.26
(5.52–9.96) for naratriptan. The mean cost (95% CI) per
pain-free patient was $55.61 ($36.50–$93.70), $56.60
($50.81–$63.44), $75.34 ($51.34–$118.61), $88.27
($77.28–$101.70) and $145.27 ($110.38–$199.27) for
almotriptan, rizatriptan, zolmitriptan, sumatriptan and
naratriptan, respectively. Cost differences between
almotriptan and rizatriptan were relatively small, with 
38 percent of simulations resulting in cost savings per
pain-free patient favoring rizatriptan. CONCLUSIONS:
Inasmuch as the results suggested that almotriptan and
rizatriptan may be similar on a cost per pain-free patient
basis, the NNT results favored rizatriptan, with approx-
imately two fewer patients needed to treat to achieve one
pain-free patient. Future economic assessments, including
endpoints such as tablet consumption per attack and 
consistency across multiple attacks, may provide further
guidance as to the most cost-effective triptan strategies.
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OBJECTIVES: Use the outcomes effectiveness measure 
of a successfully treated patient to compare the cost-
effectiveness of Eletriptan to Sumatriptan. METHODS:
Data for the economic analysis was based on pooled data
from three randomized, double blind, placebo-controlled
phase III/B clinical trials. Logistic regression with SAS
GENMOD was used to ﬁt the model and the CON-
TRAST statement was used for the comparisons of inter-
est—the numbers of successfully treated patients. Three
measure of success were analyzed: patients with headache
response within 2 hours of triptan therapy, sustained to
24 hours; patients with headache response within 1 hour
of triptan therapy, sustained to 24 hours, and patients
who were pain free within 2 hours of triptan therapy, sus-
tained to 24 hours. The cost-effectiveness measure—cost
per successfully treated patient—was calculated as a ratio
of the total cost of treating all patients to the number 
of successfully treated patients for the comparison of
Eletriptan 40mg vs. Sumatriptan 100mg. The 95% con-
ﬁdence interval for the comparison group for each
outcome effectiveness measure was calculated by boot-
strapping techniques. RESULTS: The number of success-
fully treated patients for each of the 3 outcome measures
of effectiveness was statistically signiﬁcantly greater in the
Eletriptan 40mg groups compared to the Sumatriptan
100mg groups (P-values all =<.002). The 95% conﬁdence
interval ranges for each of the Eletriptan cost-
effectiveness results are smaller and the one for the 2-hour
pain free sustained measure does not overlap that of
Sumatriptan. CONCLUSIONS: The cost per successfully
treated patient is a new composite outcome measure 
of cost-effectiveness that was consistently lower for all
patients treated with Eletriptan 40mg compared to 
Sumatriptan 100mg. Cost-effectiveness using this
outcome measure empirically demonstrates the value for
the resources spent on migraine therapy.
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OBJECTIVES: GBS is a neuromuscular disease affecting
180 to 720 Canadians each year. Patients with GBS may
be paralyzed for months, and up to 15% of affected
patients are left with a long-term disability. Until rela-
tively recently, standard therapy for GBS was a 5-day
course of PE. As an alternative to PE, more recent 
randomized trials demonstrate that intravenous IVIG is
equally effective to PE, but has fewer side effects and is
easier to administer. Since clinicians have two options for
the treatment of GBS, a cost utility analysis was con-
ducted to determine which of these two treatments is the
most cost effective. METHODS: A decision model was
developed to simulate treatment response and disease
recurrence over a 12-month time horizon. Clinical data
were obtained from a meta analysis of randomized trials.
Six experienced nurses were interviewed to obtain Health
care resource utilization data. Utility values were
obtained through interviews with 12 GBS health care
providers using the Time Trade-Off technique. RESULTS:
Based on the resource use data collected, the mean direct
cost of a 5-day treatment of IVIG and PE was $9785
(95% CI: $9637–$9933) and $7508 ($6577–$8439)
respectively. Using cost and utility estimates from IVIG
and PE, the cost per quality adjusted life year (QALY)
gained with IVIG was $35,700. In addition all of the
health care providers interviewed preferred the use of
IVIG instead of PE for their patients. CONCLUSIONS:
For the treatment of GBS, IVIG has a more favorable side
effect proﬁle and is easier to administer than PE. These
product attributes result in an incremental cost per QALY
gained that is considered economically acceptable by
current standards.
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OBJECTIVES: To examine utilization of various narcotic
analgesics that are used in pain management of occupa-
tional injuries among West Virginia Worker’s Compensa-
tion claimants. METHODS: We reviewed all claimants
(N = 20,282) who had any narcotic analgesic prescrip-
tion reimbursement during a period between July 1, 1997
and June 30, 2002. This accounted for 8% of all injury
claimants (N = 253,841) and 53.5% of all claimants 
with any prescription reimbursements (N = 37,903). We
analyzed all narcotic analgesic claims by types of drug,
extent, and duration of use and cost of the drug. We 
also studied the trend and pattern of utilization of these
medications between ﬁscal years FY1998 and FY2002.
RESULTS: The proportion of claimants with narcotic
analgesic prescription reimbursements increased by
almost 3 times from 7.8% in FY1998 to 24.4% in
FY2002. During the same period, total costs of narcotic
analgesics increased by 18 times. Most of the narcotic
analgesics were utilized in claimants who had a diagno-
sis of multiple musculoskeletal sprains (40.8%), multiple
injuries (21.2%), severe trauma (20.6%) and back injury
(7.0%). Twenty-nine percent of cases utilized more than
one narcotic analgesic. The most frequently prescribed
narcotic analgesic was hydrocodone with acetaminophen
(40.8%), followed by propoxyphene napsylate (12.6%),
Ultram (11.8%) and Oxycontin (8.9%). Although Oxy-
contin was utilized in 8.9% of the claimants, it accounted
for 34.8% of the total narcotic analgesic expenditure in
this population. Of all the narcotic analgesics, Oxycon-
tin had the highest median cost ($453 per claimant) and
median duration of use per claimant (97 days). CON-
CLUSION: Cost and utilization of narcotic analgesics
have dramatically increased over the past ﬁve years
among WV Workers Compensation claimants. Almost
90% of narcotic analgesic utilization is concentrated in
claimants with diagnosis of musculoskeletal sprains,
severe trauma, back and multiple injuries. High utiliza-
tion and duration of use of Oxycontin needs attention due
to its highly addictive nature and cost implications.
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OBJECTIVES: The objectives of this study were to deter-
mine and compare the prevalence and direct costs of back
pain in the U.S. in 1996 and 1999. METHODS: Retro-
spective analysis was conducted of the 1996 and 1999
portions of the Medical Expenditure Panel Survey
(MEPS). The MEPS collected data from nationally repre-
sentative samples of 22,601 respondents (1996) and
24,618 respondents (1999) and from respondents’ health
care and insurance providers. Data used for this study
included medical conditions and use and payments for
medical care. Back pain patients were identiﬁed using
ICD-9-CM codes determined by an expert panel of physi-
cians and professional coders as indicative of back pain.
Direct costs were calculated using patient and third-party
payments for back pain related medical events by type of
medical care. Sample estimates were weighted and pro-
jected to the population and 95% conﬁdence limits were
calculated using the Taylor expansion method. RESULTS:
There was no signiﬁcant difference in the prevalence of
back pain between 1996 (8.74%) and 1999 (9.00%).
From 1996 to 1999, total direct costs increased from
$14,701,417,650 to $25,847,917,882. Total inpatient
stay expenditures represented the largest proportion 
of this increase in direct costs, increasing from
$4,658,655,867 (mean = $10,016; 95% CL =
$9,463–$10,579) to $12,809,062,318 (mean = $17,305;
95% CL = $4,762–$29,847). Total expenditures on home
